HL7 WMG and Plenary, Sept 2016, Baltimore
Contents
DRAFT 2016 September Working Group Meeting - Baltimore, Maryland - SOA WORKING GROUP
- HL7 WGM EVENT Page Link
- [<<add link>> On-Site Meeting Schedule ]
- BROCHURE Link
Service Oriented Architecture (SOA) WORKING GROUP SESSIONS
Agenda and Meeting Minutes
Day | Date | Qtr | Time | AGENDA ITEMS | Session Leader | Room |
SUN | MAY 08 | Q1 | 9:00-10:30 | No Meeting | . | |
Q2 | 11:00-12:30 | No Meeting | . | |||
Q3 | 1:45 -3:00 | No Meeting | . | |||
Q4 | 3:30 -5:00 | No Meeting | . | |||
MON | SEP 19 | Q1 | 9:00-10:30 | No Meeting | . | |
Q2 | 11:00-12:30 | No Meeting | . | |||
Q3 | 1:45 -3:00 | Workgroup Overview / HSSP Intro / New Attendee "Jumpstart"
|
SOA | Room TBD | ||
Q4 | 3:30-5:00 | "Round Robin" Project Updates
Each active project collaborating with SOA will provide a 5-10 minute update on their current status and activities planned for the week. This is the best quarter to attend to receive an overview of all SOA-related work across all projects.
|
SOA | Room TBD | ||
TUE | SEP 20 | Q1 | 9:00-10:30 | Joint With FHIR | SOA | Room TBD |
Q2 | 11:00-12:30 | Joint w/ Patient Care
|
SOA | Room TBD | ||
Q3 | 1:45-3:00 | Patient Administration | SOA | Room TBD | ||
Q4 | 3:30 - 5:00 | SOA | Room TBD | |||
Q5 | 5:15-6:15 | . | Room TBD | |||
Q5 | 5:15-6:15 | Birds of a Feather: | . | Room TBD | ||
. | . | . | . | |||
WED | SEP 21 | Q1 | 9:00-10:30 | Joint w/EHR, Security, CBCC, SOA, FHIR
See EHR Agenda for topics Electronic Health Records Hosting
|
EHR Hosting | Room TBD |
Q2 | 11:00-12:30 | Joint w/Security | CBCC | Room TBD | ||
Q3 | 1:45 -3:00 |
|
EHR Hosting | Room TBD | ||
Q4 | 3:30 -5:00 |
|
CBCC | Room TBD | ||
THU | SEP 22 | Q1 | 9:00-10:30 | tentative FHIR Consent Profile - Discussion (CBCC-Security) see Wiki: HL7 FHIR Consent Directive Project | Room TBD | |
Q2 | 11:00-12:30 | No Meeting | . | |||
Q3 | 1:45 - 3:00 | No Meeting | . | |||
Q4 | 3:30 - 5:00 | No Meeting | . | |||
FRI | SEP 23 | Q1 | 9:00-10:30 | No Meeting | . | |
Q2 | 11:00-12:30 | No Meeting | . | |||
Q3 | 1:45 -3:00 | No Meeting | . | |||
Q4 | 3:30 -5:00 | No Meeting | . |
Q1=9:00 – 10:30 am; Q2=11:00 – 12:30 pm; Q3=1:45 – 3:00 pm; Q4=3:30 – 5:00 pm
Meeting Minutes Draft
MON Q3 and Q4 Joint CBCC - Security
- Welcome and Introductions
- Agenda Review, approval
- Joint Project report out - skipped
- International Report out -
- Europe
- Japan
- US
- Ioana
- Kathleen
- New Joint Project review
- Security and Privacy advancements since last WGM, informal/around the room
- NEW discussion items; NEW projects
- FHIR Connect-a-thon Report Out/Demo(Duane DeCouteau, Mohammad Jafari):
- Privacy Impact Assessment Project update - Suzanne
- FHIR Consent Directive work, resolution and IG creation (report out)
- Implementing FHIR based privacy consent using the Contract resource - Ioana
- Address lack of US representation at Montreal WGM
TUE Q2
- attendees:
TUE Q3
TUE Q4
- attendees:
FHIR Consent Directive work, resolution and IG creation (Suzanne @Security, Jim @CBCC) **confirm in minutes
Review, discussion of Draft Gap Analysts – BH DAM vs C-CDA and FHIR If we can avoid making new templates...create companion guides to use the current templates. Decision to be BH summary CDA R2 IG...to create a companion guide. How to tell implementers how use. FHIR DAF profile, our requirements (if any), there aren't anything new... if I were a BH vendor and I'm new to this, i.e. allergies--are there need for additional guidance? We want to include an example. This is how we would prove an allergy tolerance.
If there no additional guidance or new requirements in BH, we want to include an example. In some cases i.e. laboratory results. We have toxicology (in substance abuse); is it valuable to include a data set? Would there be value in the companion guide to point to a value set. Enter reference value sets (first version of toxicology observation identifiers...added/maintained as needed) LOINC has an exhaustive list that is broken down by substance being detected (in preliminary research)
- To what extent in BH is this helpful (Lori question)
- Presence vs absence
- Clinical pathway of test (urine, blood, saliva, etc.)
- LOINC code, Component, property (i.e. threshold), system method
Result: No new creation of new value set recommended by attendees, rather direct implantation to LOINC/Regenstreif, via link to toxicology
WED Q1 Joint w/EHR, Security, CBCC, SOA, FHIR
WED Q2
Attendees:
WED Q3 – joint with EHR
Attendees
CBCC Attendee | 1 MON Q3 | 2 MON Q4 | 3 Co-Chair | 4 DESD SD | 5 TUE Q1 | 6 TUE Q2 | 7 TUE Q3 | 8 TUE Q4 | 9 WED Q1 at EHR | 10 WED Q2 | 11 WED Q3 | 12 WED Q4 | 13 THU Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Suzanne Gonzales-WebbCBCC Co-Chair | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
[mailto: Jim Kretz] CBCC Co-Chair | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
Paul Knapp FHIR | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
[mailto: MaryKay McDaniel] | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
[mailto: Hideyuki Miyohara] Mitsubishi, HL7 Japan | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
[mailto: John Moehrke]Security Co-Chair | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
[mailto: Lisa Nelson] | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
[mailto: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
Paul Knapp FHIR | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
[mailto: Harry Rhodes], AHIMA | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
[mailto: Ioana Singureanu] | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
[mailto: Leslie Sistla] Microsoft | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
[mailto: Duane DeCouteau | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
Mohammad Jafari | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | - |
CBCC Attendee | 1 MON Q3 | 2 MON Q4 | 3 Co-Chair | 4 DESD SD | 5 TUE Q1 | 6 TUE Q2 | 7 TUE Q3 | 8 TUE Q4 | 9 WED Q1 at EHR | 10 WED Q2 | 11 WED Q3 | 12 WED Q4 | 13 THU Q1 | |
[mailto: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
[mailto: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
[mailto: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
[mailto: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | . |
CBCC Attendee | 1 MON Q3 | 2 MON Q4 | 3 Co-Chair | 4 DESD SD | 5 TUE Q1 | 6 TUE Q2 | 7 TUE Q3 | 8 TUE Q4 | 9 WED Q1 at EHR | 10 WED Q2 | 11 WED Q3 | 12 WED Q4 | 13 THU Q1 |